95501-60-3Relevant articles and documents
Structure-Based Rationale Design and Synthesis of Aurantiamide Acetate Analogues - Towards a New Class of Potent Analgesic and Anti-inflammatory Agents
Suhas, Ramesh,Channe Gowda, Dase
experimental part, p. 850 - 862 (2012/06/04)
A series of new aurantiamide acetate analogues were synthesized by modifying its N-terminal substitution and the amino acid residue. The structure of all these compounds was established on the basis of analytical and spectral studies. All the new derivatives were evaluated in vivo for their analgesic activity by tail flick method in mice and anti-inflammatory activity against carrageenan-induced oedema in albino rats at different doses (25, 50 and 100mg/kg body weight). All the compounds exhibited significant pharmacological activity with no ulcerogenic liability. In particular, pentapeptides and tricosamers (30 amino acids) containing analogues have demonstrated high potency than the reference standards. These compounds hold promise for further development.
Synthesis and crystal structure of tripeptide fragment of elastin
Doreswamy,Mahendra,Abiraj,Gowda, D. Channe,Sridhar,Prasad, J. Shashidhara
, p. 829 - 833 (2007/10/03)
Boc-Gly-Val-Pro-OBzl, a protected tripeptide fragment of repeating sequences of mammalian elastic protein elastin was synthesized and characterized by X-ray diffraction method. The sequence C24 H35 N 3 O6 crysta
Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses
Lin, Ko-Chung,Ateeq, Humayun S.,Hsiung, Sherry H.,Chong, Lillian T.,Zimmerman, Craig N.,Castro, Alfredo,Lee, Wen-Cherng,Hammond, Charles E.,Kalkunte, Sandhya,Chen, Ling-Ling,Pepinsky, R. Blake,Leone, Diane R.,Sprague, Andrew G.,Abraham, William M.,Gill, Alan,Lobb, Roy R.,Adams, Steven P.
, p. 920 - 934 (2007/10/03)
Integrin α4β1 mediates leukocyte recruitment, activation, mediator release, and apoptosis inhibition, and it plays a central role in inflammatory pathophysiology. High-affinity, selective inhibitors of α4β1, based on the Leu-Asp-Val (LDV) sequence from the alternatively spliced connecting segment-1 (CS-1) peptide of cellular fibronectin, are described that employ a novel N-terminal peptide 'cap' strategy. One inhibitor, BIO- 1211, was ~106-fold more potent than the starting peptide and exhibited tight-binding properties (k(off) = 1.4 x 10-4 s-1, K(D) = 70 pM), a remarkable finding for a noncovalent, small-molecule inhibitor of a protein receptor. BIO-1211 was also 200-fold selective for the activated form of α4β1, and it stimulated expression of ligand-induced epitopes on the integrin β1 subunit, a property consistent with occupancy of the receptor's ligand-binding site. Pretreatment of allergic sheep with a 3-mg nebulized dose of BIO-1211 inhibited early and late airway responses following antigen challenge and prevented development of nonspecific airway hyperresponsiveness to carbachol. These results show that highly selective and potent small- molecule antagonists can be identified to integrins with primary specificity for peptide domains other than Arg-Gly-Asp (RGD); they confirm the generality of integrins as small molecule targets; and they validate α4β1 as a therapeutic target for asthma.
